

Follow us on:



MEDtalks is dedicated digital platform serving as a comprehensive source of medical knowledge along with a mix of expert insight and (local) perspective, interactive features, peer-reviewed journal articles, news, and accredited continuing education.

MEDtalks offers online video programs and innovative virtual online, hybrid and traditional meetings. MEDtalks is working closely with medical societies such as ASCO and the EHA. With all content in one place, doctors will have access to even more information and insight to help improve decision-making and patient outcomes.

MEDtalks

Events presents:

Speaker Tour RCC

Challenges and best practices within the changing treatment landscape in (m)RCC


A LIVE, ACCREDITED MEETING IN BRUSSELS, ROTTERDAM AND AMSTERDAM



Prof. C. Porta
ISC Mageri, Pavia, Italy



A. van der Veldt MD PhD
Erasmus MC



Prof. J. Haanen
NKI-AvL



E. Seront MD PhD
UCL St LUC

SAVE-the-date

24 January 2019: Brussels & Rotterdam

25 January 2019: Amsterdam

This program is financially supported by:



Register now:
MEDtalks.eu/speakertour

Register now:
MEDtalks.eu/speakertour

Challenges and best practices within the changing treatment landscape in (m)RCC

With the development of new therapeutic systemic options for the treatments of mRCC, including immunotherapy, novel TKIs and combination treatment, we find ourselves standing at the verge of a new era of therapeutic possibilities. Our challenge is to find the best possible treatment algorithm for each (m)RCC patient.

During a unique Speaker Tour in Belgium and the Netherlands on the 24th and 25th of January 2019, you will meet with prof. Camillo Porta, one of the leading experts in the field of (m)RCC.

In each meeting of 1,5 hours an interactive program is offered to you. By using challenging clinical cases and short state-of-the-art lectures, prof. Camillo Porta will invite you to discuss treatment options and share experiences and best practices.

Topics:

- How to choose from the available options for first, second and third line treatment?
- What may be the impact of immunotherapy and novel TKIs on the treatment algorithm?
- What's the role of cytoreductive nephrectomy in mRCC?
- When are we ready for adjuvant therapy?

This live meeting will be submitted for accreditation for medical oncologists, urologists, pharmacists and nurse practitioners*.

“Learning on the job and sharing experiences in the best way.”

* In the Netherlands

CBZ-BE-000211

Special Guest
Professor C. Porta



ISC Maugeri, Pavia, Italy
Head of the Division of Translational Oncology
at the IRCCS Istituti Clinici Scientifici Maugeri in
Pavia, Italy and President of the Italian Nephro
Oncology Group



Prof. J. Haanen
NKI-AvL



A. van der Veldt MD PhD
Erasmus MC

Register now:
MEDtalks.eu/speakertour

This program
is financially supported by:



E. Seront MD PhD
UCL St LUC